Gilead Sciences (GILD) has now filed for conditional marketing authorization (CMA) of its antiviral medicine remdesivir for the treatment of COVID-19 with the European Medicines Agency (EMA).The EMA reports that it has now formally started its evaluation of remdesivir under a reduced timeline and an opinion could be issued within weeks. The speed will depend on the robustness of the data and whether further information is required, says the EMA.Such a short timeframe will only be possible because some data have already been assessed during the first cycle of a rolling review, which started on 30 April and ended on …read more
Source:: Yahoo Finance
